Table 1 Baseline characteristics of patients enrolled in the study
Characteristics | Derivation cohort (N, %) | Validation cohort (N, %) | P value |
|---|---|---|---|
Number of patients | 300 | 189 | NA |
Median age (%95 CI) | 74 (73 to 75) | 74 (72–75) | 0.14 |
Males/Females | 250 (83.3)/50 (16.7) | 149 (78.8)/40 (22.2) | NA |
Current | 38 (12.7) | 1 (0.5) | NA |
Ex-smokers | 199 (66.3) | 131 (69.3) | NA |
Never smokers | 63 (21.0) | 57 (30.2) | NA |
Median monocyte count (K/μL) (95% CI) | 0.60 (0.57–0.62) | 0.52 (0.50–0.58) | 0.002 |
Median RDW (95% CI) | 14.1 (13.9–14.3) | 13.7 (13.6–13.8) | < 0.001 |
Median FVC%pred (95% CI) | 77.0 (75.0–79.8) | 76.2 (71.7–80.8) | 0.69 |
Median DLCO%pred (95% CI) | 51.0 (47.1–53.8) | 41.9 ( 40.3–44.9) | < 0.001 |
Arterial Hypertension | 171 (57.0) | 111 (58.7) | NA |
Pulmonary Hypertension | 55 (18.3) | 9 (4.8) | NA |
GERD | 89 (29.6) | 26 (13.8) | NA |
Diabetes Mellitus | 65 (21.7) | 51 (27.0) | NA |
Thyroid Disorders | 25 (8.3) | 22 (11.6) | NA |
LTOT | 49 (16.3) | 65 (43.4) | NA |
Nintedanib | 123 (41.0) | 76 (40.2) | NA |
Pirfenidone | 147 (49.0) | 90 (47.6) | NA |